A Phase 2 interventional study of Memantine HCl in Autism and Pediatric Autism, sponsored by Forest Laboratories. Completed at 19 sites in United States. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2014-03-18.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.
Among the 603 studies in Autistic Disorder with a site in United States, this one is the 119th largest by enrollment of the 504 interventional ones that give a count, is one of 28 that started in 2009, is one of 95 in phase 2, and was the 244th registered.
1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.
Browse Autistic Disorder studies →123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 8–12
Vanderbilt University Medical Center · Sites in United States
Ages 36 mo–72 mo
University of Wisconsin, Madison · Sites in United States
Massachusetts General Hospital · Sites in United States
Ages 7–17
Stony Brook University · Sites in United States
Ages 12–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
603 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 122 · Phase 3 43 · Phase 4 18
First in 1997; this study’s year is marked. 28 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 49 across 813 interventional studies indexed under Autistic Disorder.
Median enrollment 44 across the 504 interventional studies, 135 across the 96 observational. Of the 408 that completed or were terminated, 143 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 603 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AbbVie has 6 studies filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
34 of the studies in Autistic Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02914951Yale UniversityCognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability | 2026-12 |
| NCT06627205Stanford UniversitySleep Restriction Therapy (SRT) for Sleep Problems in Children With Autism | 2026-12 |
| NCT04805957Rutgers, The State University of New JerseyValidation Digital Bio-markers During Sulforaphane Treatment. | 2026-12-01 |
| NCT07421830Northeastern UniversityAn Empowering Parent Training Intervention to Increase Physical Activity in Preschool Aged Children With Autism | 2026-12-31 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
Add all 34 to your calendar (.ics) → With an account.
Among the 603 studies in Autistic Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of autism in pediatric patients.
This is a 48-week multicenter extension study comprised of a 6-week double-blind dose-titration period followed by a 42-week open-label maintenance period.
In the Forest autism trials conducted in children ages 6-12, dosing with an extended release formulation of memantine was weight-based. These weight based dose limits were selected to ensure exposure in terms of area under the curve (AUC) was less than the predefined limit of 2100 ng∙h/mL that represented a 10-fold lower exposure than observed at the NOAEL (No observed adverse effect level) of 15 mg/kg/day in juvenile rats.
The weight-based dose limits in these studies were as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Once daily oral administration of memantine for 48 weeks: 6-week double-blind dose-titration period followed by a 42-week maintenance period.
Drug: Memantine HCl
Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
Also known as: Namenda, Namenda XR
Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE)
Number of patients who experienced one or more TEAEs during the study
Time frame: From Visit 1 (Week 1) to 30 days after Visit 8 (Week 48)
Patients who completed the lead-in study MEM-MD-57A (NCT00872898) were eligible to enroll in this study. A total of 19 study centers in the United States enrolled patients.
| Milestone | Memantine |
|---|---|
| Started | 102 |
| Completed | 66 |
| Not completed | 36 |
| Withdrew: Adverse event | 9 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Lost to follow-up | 10 |
| Withdrew: Other reason | 3 |
| Withdrew: Inclusion/exclusion criteria not met | 1 |
Number of patients who experienced one or more TEAEs during the study
| participants | Memantine |
|---|---|
| Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE) | 85 |
Collected over Adverse event data was collected over a 40 month period from November 2009 to March 2013 at 19 study sites in the US.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo to Memantine | — | 1/50 (2%) | 37/50 (74%) |
| Memantine to Memantine | — | 0/52 (0%) | 37/52 (71.2%) |
| Event | Placebo to Memantine | Memantine to Memantine |
|---|---|---|
| Lobar pneumoniaInfections and infestations | 1/50 | 0/52 |
| Event | Placebo to Memantine | Memantine to Memantine |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/50 | 10/52 |
| Seasonal allergyImmune system disorders | 7/50 | 2/52 |
| VomitingGastrointestinal disorders | 6/50 | 2/52 |
| ConstipationGastrointestinal disorders | 5/50 | 2/52 |
| Weight increasedInvestigations | 5/50 | 4/52 |
| AggressionPsychiatric disorders | 5/50 | 3/52 |
| InsomniaPsychiatric disorders | 5/50 | 3/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/50 | 5/52 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 5/50 | 3/52 |
| IrritabilityGeneral disorders | 2/50 | 5/52 |
| Age, Continuous(years) | Memantine |
|---|---|
| Years | 9.1 ± 2.2 |
| Sex: Female, Male(Participants) | Memantine |
|---|---|
| Female | 15 |
| Male | 87 |
| Race/Ethnicity, Customized(participants) | Memantine |
|---|---|
| White | 86 |
| Black | 2 |
| Asian | 9 |
| American Indian or Alaska Native | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Other | 4 |
| Race/Ethnicity, Customized(participants) | Memantine |
|---|---|
| Hispanic or Latino | 11 |
| Non-Hispanic or Latino | 91 |
| Region of Enrollment(participants) | Memantine |
|---|---|
| United States | 102 |
The record gives a start of Nov 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine